

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

PHASE IB CLINICAL TRIAL OF JMT206 INJECTION FOR WEIGHT MANAGEMENT IN ADULT PATIENTS WITH OVERWEIGHT OR OBESITY OFFICIALLY INITIATED AT THE FIRST STUDY CENTRE IN CHINA

The Board of Directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the Phase Ib clinical trial (JMT206–003) of JMT206 Injection (the “**Product**”), developed by the Group, for weight management in adult patients with overweight or obesity has been officially initiated at the first study centre in China.

The Product is registered as a Class 1 therapeutic biological product and is a recombinant fully human anti-activin receptor type IIA (“**ActR-IIA**”) and type IIB (“**ActR-IIB**”) monoclonal antibody. It can specifically bind to ActR-IIA and ActR-IIB on the surface of target cell membranes, blocking the activation of the ActR-IIA and ActR-IIB signalling pathways, thereby exerting effects such as promoting an increase in muscle mass and reducing body weight. Pre-clinical studies demonstrated that the Product exhibited favourable muscle-building and fat-reducing effects, alongside a good safety and tolerability profile.

In November 2025, the Group obtained the Notice of Approval for Clinical Trial of Drug issued by the National Medical Products Administration of the People’s Republic of China for the Product regarding the overweight or obesity indication, and initiated the Phase I clinical trial following the approval. The Phase I clinical trial data preliminarily verified the safety, pharmacokinetic and pharmacodynamic profiles of the Product in healthy participants.

The Phase Ib clinical trial initiated this time is a randomised, double-blind, placebo parallel-controlled clinical trial aimed at evaluating the safety, tolerability, pharmacokinetic and pharmacodynamic profiles of multiple subcutaneous injections of the Product, either as monotherapy or in combination with semaglutide injection, in obese participants. At present, the recruitment and screening of participants for this clinical trial are being actively advanced.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 29 September 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.